Melanoma: all 3,073 studies

Page 30 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular MelanomaCompletedNCT00062933Phase 2
• Study of Karenitecin (BNP1350) to Treat Malignant MelanomaCompletedNCT00062491Phase 2
• Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic MelanomaCompletedNCT00062036Phase 1/2
• CP-461 in the Treatment of Patients With Advanced MelanomaTerminatedNCT00060710Phase 2
• Tipifarnib in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00060125Phase 2
• Boron Neutron Capture Therapy in Treating Patients With MelanomaCompletedNCT00059800Phase 2
• Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00058279Phase 1/2
• Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.CompletedNCT00057616Phase 3
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00056134Phase 1/2
• Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaCompletedNCT00055562Phase 2/3
• Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00054535Phase 2
• Perifosine in Treating Patients With Metastatic or Recurrent Malignant MelanomaCompletedNCT00053781Phase 2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00053391Phase 1/2
• Vaccine Therapy for Patients With Stage IV MelanomaStatus unknownNCT00052156Phase 3
• Vaccine Therapy for Patients With Stage III MelanomaStatus unknownNCT00052130Phase 3
• Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic MelanomaCompletedNCT00050102Phase 2
• Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II MelanomaCompletedNCT00049010Not applicable
• Biological Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00045357Phase 1
• Biological Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00045149Phase 1
• Phase II Trial of Allovectin-7® for Metastatic MelanomaCompletedNCT00044356Phase 2
• Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00042783Phase 2
• Immunotherapy With Autologous Dexosomes for Patients With Stage IV MelanomaSuspendedNCT00042497Phase 2
• Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the LiverCompletedNCT00041808Phase 1/2
• Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the BrainCompletedNCT00039572Phase 1/2
• Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant MelanomaCompletedNCT00039325Phase 1/2
• Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the LiverStatus unknownNCT00039234Phase 3
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV MelanomaCompletedNCT00039000Phase 3
• Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic MelanomaStatus unknownNCT00037037Phase 1
• Vaccine Therapy in Treating Patients With Melanoma of the EyeTerminatedNCT00036816Phase 3
• BMS-247550 in Treating Patients With Stage IV MelanomaCompletedNCT00036764Phase 2
• EPO906 Therapy in Patients With Advanced MelanomaCompletedNCT00035165Phase 2
• Study of gp75 Vaccine in Patients With Stage III and IV MelanomaCompletedNCT00034554Phase 1
• Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00033228Phase 1/2
• Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00032045Phase 2
• Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
• Decitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00030615Phase 1
• ADI-PEG in Patients With Metastatic MelanomaCompletedNCT00029900Phase 1
• Novel Adjuvants for Peptide-Based Melanoma VaccinesCompletedNCT00028431Phase 1
• Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00027742Phase 2
• Imatinib Mesylate in Treating Patients With Metastatic MelanomaCompletedNCT00027586Phase 2
• Eligibility Screening for the NIH Intramural Research Program Clinical ProtocolsCompletedNCT00026754
• Interferon Alfa and Thalidomide in Treating Patients With Stage IV MelanomaCompletedNCT00026520Phase 2
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00026143Phase 2
• Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During SurgeryCompletedNCT00025181Phase 1
• Isotretinoin in Preventing Skin CancerCompletedNCT00025012Not applicable
• PS-341 in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00024011Phase 2
• Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00023647Phase 1
• Vaccine Therapy in Treating Patients With Metastatic MelanomaStatus unknownNCT00022568Phase 1
• CCI-779 in Treating Patients With Metastatic MelanomaCompletedNCT00022464Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous TreatmentCompletedNCT00022438Phase 2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00021164Phase 2
• Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the BrainTerminatedNCT00020839Phase 3
• Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00020540Phase 1
• Vaccine Therapy in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT00020475Phase 2
• Vaccine Therapy in Treating Patients With Refractory Metastatic MelanomaCompletedNCT00020397Phase 2
• Vaccine Therapy in Treating Patients With MelanomaCompletedNCT00020358Phase 2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
• Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00019994Phase 2
• Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic MelanomaCompletedNCT00019890Phase 2
• Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00019734Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019721Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019669Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019487Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019448Phase 2
• flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell CancerCompletedNCT00019396Phase 2
• Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic MelanomaCompletedNCT00019383Phase 2
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00019214Phase 1/2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic MelanomaCompletedNCT00019175Phase 1
• Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory LymphomasCompletedNCT00019019Phase 1
• Vaccine Therapy in Treating Patients With Metastatic MelanomaStatus unknownNCT00017355Phase 1
• Thalidomide and SU5416 in Treating Patients With Metastatic MelanomaCompletedNCT00017316Phase 2
• Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the LungCompletedNCT00017121Phase 1
• Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant MelanomaCompletedNCT00016263Phase 3
• Biological Therapy and Temozolomide in Treating Patients With Metastatic MelanomaStatus unknownNCT00016055Phase 1
• E7070 in Treating Patients With Stage IV MelanomaCompletedNCT00014625Phase 2
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid TumorsCompletedNCT00014456Phase 1
• Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With SurgeryCompletedNCT00014092Phase 2
• Vaccine Therapy in Treating Patients With Stage IV or Recurrent MelanomaCompletedNCT00012064Phase 1/2
• Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV MelanomaStatus unknownNCT00010309Phase 1/2
• Photodynamic Therapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00007969Phase 1/2
• Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00006385Phase 2
• Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
• Interferon Alfa Following Surgery in Treating Patients With Stage III MelanomaStatus unknownNCT00006249Phase 3
• Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant MelanomaCompletedNCT00006243Not applicable
• Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV MelanomaCompletedNCT00006233Phase 2
• Thalidomide and Dacarbazine for Metastatic MelanomaStatus unknownNCT00006200Phase 2
• Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With SurgeryWithdrawnNCT00006126Phase 1
• Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV MelanomaTerminatedNCT00006113Phase 2
• Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV MelanomaStatus unknownNCT00006035Phase 1
• Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney CancerCompletedNCT00006022Phase 1
• SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedTerminatedNCT00006003Phase 2
• Flavopiridol in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00005971Phase 2
• Irofulven in Treating Patients With Stage IV MelanomaCompletedNCT00005968Phase 2
• O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic MelanomaCompletedNCT00005961Phase 2
• Vaccine Plus Interleukin-2 in Treating Patients With Advanced MelanomaCompletedNCT00005949Phase 2
• Gene Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00005943Phase 1
• Nitrocamptothecin in Treating Patients With Metastatic MelanomaCompletedNCT00005875Phase 2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV MelanomaTerminatedNCT00005841Phase 1

← Melanoma overview